Cellular communication via microparticles: Role in transfer of multidrug resistance in cancer

Future Oncology

Volumn 10, Issue 4, 2014, Pages 655-669

  Jaiswal, Ritu ^a,b   Raymond Grau, Georges Emile ^b   Bebawy, Mary ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

cancer; CD44; cellular communication; ezrin; microparticle; microRNA; multidrug resistance; multidrug resistant associated protein 1; p glycoprotein; trait dominance

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EZRIN; HERMES ANTIGEN; MEMBRANE PHOSPHOLIPID; MEMBRANE PROTEIN; METHOTREXATE; MICRORNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; PHOSPHATIDYLSERINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; APOPTOSIS; BIOGENESIS; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL ADHESION; CELL ANCHORAGE; CELL COMMUNICATION; CELL CONTACT; CELL MEMBRANE; CELL MEMBRANE TRANSPORT; CELL MOTILITY; CELL SURVIVAL; CROSS RESISTANCE; CYTOSKELETON; DRUG SENSITIVITY; HUMAN; INTRACELLULAR SIGNALING; MEMBRANE MICROPARTICLE; MEMBRANE VESICLE; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; STRUCTURAL HOMOLOGY; TARGET CELL; TUMOR ESCAPE; UPREGULATION; ANIMAL; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PROTEIN TRANSPORT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL COMMUNICATION; CELL-DERIVED MICROPARTICLES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS; P-GLYCOPROTEINS; PHENOTYPE; PROTEIN TRANSPORT;

EID: 84899482183     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.230     Document Type: Review

References (118)

1. Longley D, Johnston P. Molecular mechanisms of drug resistance. J. Pathol. 205(2), 275-292 (2005
2. Gong J, Jaiswal R, Mathys JM, Combes V, Grau GE, Bebawy M. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat. Rev. 38(3), 226-234 (2012
3. Bebawy M, Morris MB, Roufogalis BD. A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles. Anal. Biochem. 268(2), 270-277 (1999
4. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2(1), 48-58 (2002
5. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5(3), 219-234 (2006
6. Sharom FJ. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9(1), 105-127 (2008
7. Benderra Z, Faussat AM, Sayada L et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin. Cancer Res. 10(23), 7896-7902 (2004
8. Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89(9), 3323-3329 (1997
9. Ivy SP, Olshefski RS, Taylor BJ, Patel KM, Reaman GH. Correlation of P-glycoprotein expression and function in childhood acute leukemia: A children's cancer group study. Blood 88(1), 309-318 (1996
10. Chan H, Thorner P, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol. 8(4), 689-704 (1990
11. Chan HS, Haddad G, Thorner PS et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med. 325(23), 1608-1614 (1991
12. Gottesman MM. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53(1), 615-627 (2002
13. Baldini N, Scotlandi K, Barbanti-Brodano G et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med. 333(21), 1380-1385 (1995
14. Linn SC, Giaccone G, van Diest PJ et al. Prognostic relevance of P-glycoprotein expression in breast cancer. Ann. Oncol. 6(7), 679-685 (1995
15. Hsia TC, Lin CC, Wang JJ, Ho ST, Kao A. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistancerelated protein expression. Lung 180(3), 173-179 (2002
16. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN. The expression of drug resistance gene products during the progression of human prostate cancer. Clin. Cancer Res. 4(6), 1393-1403 (1998
17. Jin J, Wang FP, Wei H, Liu G. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother. Pharmacol. 55(2), 179-188 (2005
18. Berger W, Setinek U, Hollaus P et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: Prognostic implications. J. Cancer Res. Clin. Oncol. 131(6), 355-363 (2005
19. Benyahia B, Huguet S, Decleves X et al. Multidrug resistance-Associated protein MRP1 expression in human gliomas: Chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J. Neurooncol. 66(1-2), 65-70 (2004
20. Koh EH, Chung HC, Lee KB et al. The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy. Yonsei Med. J. 33(2), 137-142 (1992
21. Maitra R, Halpin PA, Karlson KH et al. Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression. Biochem. J. 355(Pt 3), 617-624 (2001
22. Cole SP, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258(5088), 1650-1654 (1992
23. Almquist KC, Loe DW, Hipfner DR, Mackie JE, Cole SP, Deeley RG. Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell. Cancer Res. 55(1), 102-110 (1995
24. Munoz M, Henderson M, Haber M, Norris M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 59(12), 752-757 (2007
25. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: The multidrug resistance associated proteins. J. Natl Cancer Inst. 92(16), 1295-1302 (2000
26. Bakos E, Homolya L. Portrait of multifaceted transporter, the multidrug resistanceassociated protein 1 (MRP1/ABCC1). Pflugers Arch. 453(5), 621-641 (2007
27. Hsia TC, Shen YY, Yen RF, Kao CH, Changlai SP. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. Neoplasma 49(4), 267-271 (2002
28. Nooter K, De La Riviere GB, Klijn J, Stoter G, Foekens J. Multidrug resistance protein in recurrent breast cancer. Lancet 349(9069), 1885-1886 (1997
29. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Expression of the gene for multidrug-resistance-Associated protein and outcome in patients with neuroblastoma. N. Engl. J. Med. 334(4), 231-238 (1996
30. Higgins CF, Callaghan R, Linton KJ, Rosenberg MF, Ford RC. Structure of the multidrug resistance P-glycoprotein. Semin. Cancer Biol. 8(3), 135-142 (1997
31. Altenberg GA. Structure of multidrugresistance proteins of the ATP-binding cassette (ABC) superfamily. Curr. Med. Chem. Anticancer Agents 4(1), 53-62 (2004
32. Lu JF, Luk F, Gong J, Jaiswal R, Grau GE, Bebawy M. Microparticles mediate MRP1 intercellular transfer and the re-Templating of intrinsic resistance pathways. Pharmacol. Res. 76C, 77-83 (2013
33. Szakacs G, Annereau JP, Lababidi S et al. Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell 6(2), 129-137 (2004
34. Robbiani DF, Finch RA, Jager D, Muller WA, Sartorelli AC, Randolph GJ. The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 103(5), 757-768 (2000
35. van De Ven R, Scheffer GL, Reurs AW et al. A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. Blood 112(6), 2353-2359 (2008
36. van De Ven R, Scheffer GL, Scheper RJ, De Gruijl TD. The ABC of dendritic cell development and function. Trends Immunol. 30(9), 421-429 (2009
37. Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F. The functions and structure of ABC transporters: Implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets 7(7), 893-909 (2006
38. Luciani F, Molinari A, Lozupone F et al. P-glycoprotein-Actin association through ERM family proteins: A role in P-glycoprotein function in human cells of lymphoid origin. Blood 99(2), 641-648 (2002
39. Jeon S, Kim NH, Kim JY, Lee AY. Stem cell factor induces ERM proteins phosphorylation through PI3K activation to mediate melanocyte proliferation and migration. Pigment Cell Melanoma Res. 22(1), 77-85 (2009
40. Killock DJ, Parsons M, Zarrouk M et al. In vitro and in vivo characterization of molecular interactions between calmodulin, ezrin/ radixin/moesin, and L-selectin. J. Biol. Chem. 284(13), 8833-8845 (2009
41. Amieva MR, Furthmayr H. Subcellular localization of moesin in dynamic filopodia, retraction fibers, and other structures involved in substrate exploration, attachment, and cell-cell contacts. Exp. Cell Res. 219(1), 180-196 (1995
42. Puddu P, Fais S, Luciani F et al. Interferongamma up-regulates expression and activity of P-glycoprotein in human peripheral blood monocyte-derived macrophages. Lab. Invest. 79(10), 1299-1309 (1999
43. Dallas S, Miller DS, Bendayan R. Multidrug resistance-Associated proteins: Expression and function in the central nervous system. Pharmacol. Rev. 58(2), 140-161 (2006
44. Jodoin J, Demeule M, Fenart L et al. P-glycoprotein in blood-brain barrier endothelial cells: Interaction and oligomerization with caveolins. J. Neurochem. 87, 1010-1023 (2003
45. Fu D, Roufogalis BD. Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation. Am. J. Physiol. Cell Physiol. 292(4), C1543-C1552 (2007
46. Kikuchi S, Hata M, Fukumoto K et al. Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes. Nat. Genet. 31(3), 320-325 (2002
47. Jaiswal R, Luk F, Dalla PV, Grau GER, Bebawy M. Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PLoS ONE 8(4), e61515 (2013
48. Birch M, Mitchell S, Hart IR. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res. 51(24), 6660-6667 (1991
49. Miletti-Gonzalez KE, Chen S, Muthukumaran N et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res. 65(15), 6660-6667 (2005
50. Colone M, Calcabrini A, Toccacieli L et al. The multidrug transporter P-glycoprotein: A mediator of melanoma invasion? J. Invest. Dermatol. 128(4), 957-971 (2007
51. Jung T, Castellana D, Klingbeil P et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia 11(10), 1093-1105 (2009
52. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316(6031), 817-819 (1985
53. Shen DW, Fojo A, Chin JE et al. Human multidrug-resistant cell lines: Increased mdr1 expression can precede gene amplification. Science 232(4750), 643-645 (1986
54. Lee CH, Bradley G, Ling V. Increased P-glycoprotein messenger RNA stability in rat liver tumors in vivo. J. Cell. Physiol. 177(1), 1-12 (1998
55. Sukhai M, Piquette-Miller M. Regulation of the multidrug resistance genes by stress signals. J. Pharm. Pharm. Sci. 3(2), 268-280 (2000
56. Levchenko A, Mehta BM, Niu X et al. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc. Natl Acad. Sci. USA 102(6), 1933-1938 (2005
57. Skog J, Wurdinger T, Van Rijn S et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10(12), 1470-1476 (2008
58. Brown R, Kabani K, Favaloro J et al. CD86+ or HLA-G+ myeloma cells are associated with poor prognosis and once acquired by trogocytosis create novel Tregacq cells. Blood 15, 15 (2012
59. Pasquier J, Galas L, Boulange-Lecomte C et al. Different modalities of intercellular membrane exchanges mediate cell-To-cell P-glycoprotein transfers in MCF-7 breast cancer cells. J. Biol. Chem. 287(10), 7374-7387 (2012
60. Watkins SC, Salter RD. Functional connectivity between immune cells mediated by tunneling nanotubules. Immunity 23(3), 309-318 (2005
61. Sherer NM, Mothes W. Cytonemes and tunneling nanotubules in cell-cell communication and viral pathogenesis. Trends Cell Biol. 18(9), 414-420 (2008
62. Mack M, Kleinschmidt A, Bruhl H et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: A mechanism for cellular human immunodeficiency virus 1 infection. Nat. Med. 6(7), 769-775 (2000
63. Bebawy M, Combes V, Lee E et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 23(9), 1643-1649 (2009
64. Jaiswal R, Luk F, Gong J, Mathys JM, Grau GE, Bebawy M. Microparticle conferred microRNA profiles - implications in the transfer and dominance of cancer traits. Mol. Cancer 11(1), 37 (2012
65. Jaiswal R, Gong J, Sambasivam S et al. Microparticle-Associated nucleic acids mediate trait dominance in cancer. FASEB J. 26(1), 420-429 (2012
66. Gong J, Luk F, Jaiswal R, George AM, Grau GE, Bebawy M. Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance. Eur. J. Pharmacol. 721, 116-125 (2013
67. Coltel N, Combes V, Wassmer SC, Chimini G, Grau GE. Cell vesiculation and immunopathology: Implications in cerebral malaria. Microbes Infect. 8(8), 2305-2316 (2006
68. Mackenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A. Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 15(5), 825-835 (2001
69. Combes V, Coltel N, Alibert M et al. ABCA1 gene deletion protects against cerebral malaria: Potential pathogenic role of microparticles in neuropathology. Am. J. Pathol. 166(1), 295-302 (2005
70. Smalley DM, Root KE, Cho H, Ross MM, Ley K. Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles. Thromb. Haemost. 97(1), 67-80 (2007
71. Pankoui Mfonkeu JB, Gouado I, Fotso Kuate H et al. Elevated cell-specific microparticles are a biological marker for cerebral dysfunctions in human severe malaria. PLoS ONE 5(10), e13415 (2010
72. Combes V, Simon A-C, Grau G-E et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J. Clin. Invest. 104(1), 93-102 (1999
73. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: Two sides of the coin. Physiology (Bethesda) 20(1), 22-27 (2005
74. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb. Haemost. 101(3), 439-451 (2009
75. Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb. Res. 123(1), 8-23 (2008
76. Horstman LL, Ahn YS. Platelet microparticles: A wide-Angle perspective. Crit. Rev. Oncol. Hematol. 30(2), 111-142 (1999
77. Combes V, Coltel N, Faille D, Wassmer SC, Grau GE. Cerebral malaria: Role of microparticles and platelets in alterations of the blood-brain barrier. Int. J. Parasitol. 36(5), 541-546 (2006
78. Ginestra A, Monea S, Seghezzi G et al. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J. Biol. Chem. 272(27), 17216-17222 (1997
79. Dolo V, D'ascenzo S, Violini S et al. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin. Exp. Metastasis 17(2), 131-140 (1999
80. Kim CW, Lee HM, Lee TH, Kang C, Kleinman HK, Gho YS. Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Res. 62(21), 6312-6317 (2002
81. Angelucci A, D'Ascenzo S, Festuccia C et al. Vesicle-Associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin. Exp. Metastasis 18(2), 163-170 (2000
82. Dvorak HF, Van DeWater L, Bitzer AM et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res. 43(9), 4434-4442 (1983
83. Pasquet JM, Dachary-Prigent J, Nurden AT. Calcium influx is a determining factor of calpain activation and microparticle formation in platelets. Eur. J. Biochem. 239(3), 647-654 (1996
84. Skog J, Wurdinger T, van Rijn S et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10(12), 1470-1476 (2008
85. Lane JD, Allan VJ, Woodman PG. Active relocation of chromatin and endoplasmic reticulum into blebs in late apoptotic cells. J. Cell Sci. 118(17), 4059-4071 (2005
86. Schiller M, Bekeredjian-Ding I, Heyder P, Blank N, Ho AD, Lorenz HM. Autoantigens are translocated into small apoptotic bodies during early stages of apoptosis. Cell Death Differ. 15(1), 183-191 (2007
87. Reich CF 3rd, Pisetsky DS. The content of DNA and RNA in microparticles released by Jurkat and HL-60 cells undergoing in vitro apoptosis. Exp. Cell Res. 315(5), 760-768 (2009
88. El-Hefnawy T, Raja S, Kelly L et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin. Chem. 50(3), 564-573 (2004
89. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110(1), 13-21 (2008
90. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res. 32(Suppl. 1), D109-D111 (2004
91. Schetter AJ, Harris CC Plasma microRNAs: A potential biomarker for colorectal cancer? Gut 58(10), 1318-1319 (2009
92. Ambros V. MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell 113(6), 673-676 (2003
93. Tsang WP, Kwok TT. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 13(10), 1215-1222 (2008
94. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: Key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27(45), 5959-5974 (2008
95. Chen GQ, Zhao ZW, Zhou HY, Liu YJ, Yang HJ. Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med. Oncol. 27(2), 406-415 (2010
96. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10(10), 704-714 (2009
97. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 57(1), 84-91 (2011
98. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9(6), 654-659 (2007
99. Yuan A, Farber EL, Rapoport AL et al. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS ONE 4(3), 6 (2009
100. Rui W, Bing F, Hai-Zhu S, Wei D, Long-Bang C. Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J. Cell. Mol. Med. 14(1-2), 206-214 (2010
101. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 26(19), 2799-2803 (2007
102. Mishra PJ, Humeniuk R, Longo-Sorbello GS, Banerjee D, Bertino JR. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl Acad. Sci. USA 104(33), 13513-13518 (2007
103. Yang H, Kong W, He L et al. MicroRNA expression profiling in human ovarian cancer: MiR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68(2), 425-433 (2008
104. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int. J. Cancer 127(8), 1785-1794 (2010
105. Kovalchuk O, Filkowski J, Meservy J et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 7(7), 2152-2159 (2008
106. Zhu H, Wu H, Liu X et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol. 76(5), 582-588 (2008
107. Liang Z, Wu H, Xia J et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-Associated protein 1. Biochem. Pharmacol. 79(6), 817-824 (2010
108. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with PKC-epsilon promotes oncogenic signaling by the stem cell marker, Nanog and the production of microRNA-21 leading to downregulation of the tumor suppressor protein, PDCD4, anti-Apoptosis and chemotherapy resistance in breast tumor cells. J. Biol. Chem. 284(39), 26533 -26546 (2009
109. Xu K, Liang X, Shen K et al. MiR-297 modulate multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Biochem. J. 7, 7 (2012
110. Abid Hussein MN, Böing AN, Sturk A, Hau CM, Nieuwland R. Inhibition of microparticle release triggers endothelial cell apoptosis and detachment. Thromb. Haemost. 98(5), 917-1154 (2007
111. Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen. Pharmacol. 27(8), 1283-1291 (1996
112. Faille D, Combes V, Mitchell AJ et al. Platelet microparticles: A new player in malaria parasite cytoadherence to human brain endothelium. FASEB J. 23(10), 3449-3458 (2009
113. Kim HK, Song KS, Park YS et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: Possible role of a metastasis predictor. Eur. J. Cancer 39(2), 184-191 (2003
114. Tesselaar ME, Romijn FP, Van Der Linden IK et al. Microparticle- Associated tissue factor activity: A link between cancer and thrombosis? J. Thromb. Haemost. 5(3), 520-527 (2007
115. Toth B, Nieuwland R, Liebhardt S et al. Circulating microparticles in breast cancer patients: A comparative analysis with established biomarkers. Anticancer Res. 28(2A), 1107-1112 (2008
116. Trappenburg MC, van Schilfgaarde M, Bredewold EO et al. Elevated numbers and altered subsets of procoagulant microparticles in breast cancer patients using endocrine therapy. Thromb. Res. 127(4), 363-369 (2011
117. Rank A, Nieuwland R, Crispin A et al. Clearance of platelet microparticles in vivo. Platelets 22(2), 111-116 (2011
118. Roseblade A, Luk F, Rawling T, Ung A, Grau G, Bebawy M. Cell-derived microparticles: New targets in the therapeutic management of disease. J. Pharm. Pharmaceut. Sci. 16(2), 238-253 (2013